A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Arvinas, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 15,025 shares of ARVN stock, worth $280,967. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,025
Previous 10,062 49.32%
Holding current value
$280,967
Previous $247,000 16.6%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 07, 2025

BUY
$17.83 - $28.04 $88,490 - $139,162
4,963 Added 49.32%
15,025 $288,000
Q2 2024

Jul 29, 2024

BUY
$24.46 - $40.4 $57,798 - $95,465
2,363 Added 30.69%
10,062 $267,000
Q1 2024

Apr 25, 2024

SELL
$36.38 - $52.31 $48,530 - $69,781
-1,334 Reduced 14.77%
7,699 $317,000
Q4 2023

Jan 30, 2024

BUY
$14.19 - $42.33 $22,860 - $68,193
1,611 Added 21.71%
9,033 $371,000
Q2 2023

Aug 07, 2023

BUY
$21.73 - $31.43 $37,419 - $54,122
1,722 Added 30.21%
7,422 $184,000
Q1 2023

May 08, 2023

SELL
$26.15 - $37.26 $7,661 - $10,917
-293 Reduced 4.89%
5,700 $155,000
Q4 2022

Feb 01, 2023

SELL
$32.47 - $57.24 $31,236 - $55,064
-962 Reduced 13.83%
5,993 $205,000
Q3 2022

Nov 09, 2022

BUY
$41.87 - $57.99 $74,361 - $102,990
1,776 Added 34.29%
6,955 $309,000
Q1 2022

Apr 21, 2022

SELL
$60.27 - $81.57 $16,996 - $23,002
-282 Reduced 5.16%
5,179 $349,000
Q4 2021

Feb 01, 2022

BUY
$65.85 - $96.21 $67,891 - $99,192
1,031 Added 23.27%
5,461 $449,000
Q3 2021

Nov 15, 2021

BUY
$73.2 - $107.87 $36,600 - $53,935
500 Added 12.72%
4,430 $364,000
Q2 2021

Jul 30, 2021

SELL
$60.45 - $84.26 $209,761 - $292,382
-3,470 Reduced 46.89%
3,930 $303,000
Q1 2021

May 03, 2021

BUY
$58.19 - $91.37 $248,529 - $390,241
4,271 Added 136.5%
7,400 $489,000
Q2 2020

Jul 28, 2020

BUY
$29.88 - $56.74 $62,598 - $118,870
2,095 Added 202.61%
3,129 $105,000
Q1 2020

May 06, 2020

BUY
$33.0 - $54.5 $34,122 - $56,353
1,034 New
1,034 $42,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $995M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.